221030-79-1

Basic information

• Product Name: 4-bromo-2-fluoro-1-methylthiobenzene
• Synonyms: (4-Bromo-2-fluorophenyl)(methyl)sulfane;4-bromo-2-fluoro-1-methylthiobenzene;4-Bromo-2-fluorothioanisole;Benzene, 4-bromo-2-fluoro-1-(methylthio)-
• CAS NO: 221030-79-1
• Molecular Formula: C₇H₆BrFS
• Molecular Weight: 221.0899432
• Mol File: 221030-79-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-bromo-2-fluoro-1-methylthiobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2-fluoro-1-methylthiobenzene(221030-79-1)
• EPA Substance Registry System: 4-bromo-2-fluoro-1-methylthiobenzene(221030-79-1)

Safety Data

• Hazardous Substances Data: 221030-79-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-2-fluoro-1-methylthiobenzene is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into complex molecular structures, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-2-fluoro-1-methylthiobenzene serves as a key component in the production of pesticides and other crop protection agents, leveraging its chemical properties to enhance the effectiveness of these products.
Used in Materials Science:
4-bromo-2-fluoro-1-methylthiobenzene is utilized in materials science research for its potential to contribute to the development of novel materials with unique properties, such as improved stability or specific interactions with other molecules.
Used in Organic Synthesis:
As a building block in organic synthesis, 4-bromo-2-fluoro-1-methylthiobenzene is employed for the preparation of a variety of organic molecules, including those with potential applications in chemical research, pharmaceuticals, and other industries.

Upstream product

• 74-88-4 methyl iodide 
• 174414-93-8 4-bromo-2-fluorobenzenethiol 
• 655-20-9 2-fluorothioanisole 

Downstream Products

• 138709-30-5 1-bromo-3,4-bis(methylthio)benzene 
• 648904-84-1 4-bromo-2-fluoro-1-(methylsulfonyl)benzene 
• 1228839-16-4 2-fluoro-4-(2-methyl-allyl)-1-methylsulfanyl-benzene 
• 1351499-74-5 2-(3-fluoro-4-methylsulfanyl-phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Relevant articles and documents

NOVEL COMPOUNDS AS GPR119 AGONISTS

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

Metabolism-guided design of short-acting calcium-sensing receptor antagonists

As part of a strategy to deliver short-acting calcium-sensing receptor (CaSR) antagonists, the metabolically labile thiomethyl functionality was incorporated into the zwitterionic amino alcohol derivative 3 with the hope of increasing human clearance through oxidative metabolism, while delivering a pharmacologically inactive sulfoxide metabolite. The effort led to the identification of thioanisoles 22 and 23 as potent and orally active CaSR antagonists with a rapid onset of action and short pharmacokinetic half-lives, which led to a rapid and transient stimulation of parathyroid hormone in a dose-dependent fashion following oral administration to rats. On the basis of the balance between target pharmacology, safety, and human disposition profiles, 22 and 23 were advanced as clinical candidates for the treatment of osteoporosis.

1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

The present invention is directed to novel 1,1 -(dimethyl-ethylamino)-2- hydroxy-propoxy]-ethyl}-3-methyl-biphenyl-4-carboxylic acid derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variable R1 is as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES

The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases

SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS

According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof.

Non-nucleoside reverse transcriptase inhibitors

This invention relates to novel pyridazinone derivatives of formula I wherein R1-R4, R7, R8 and X1 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated